"NYU Langone Health said on Thursday that it has received 510(k) clearance from the US Food and Drug Administration for its Genome PACT genetic test for solid tumors...Genome PACT — short for profiling of actionable cancer targets — uses next-generation sequencing to detect cancer-linked mutations in 607 genes in tumor cells in order to match patients with approved treatments targeting their specific disease-causing mutations."